Baker Bros. Advisors 13F: Adds $5.1M to DSGN Stake

Baker Bros. Advisors grew its position in Design Therapeutics, Inc. (NasdaqGS: DSGN) by 15.8% during the most recent reporting period, according to its latest Form 13F filing with the Securities and Exchange Commission. The investment firm purchased 352,879 shares of the clinical-stage biotechnology company, bringing its total holdings to 2,585,978 shares. At the close of the reporting period, the fund's total stake was valued at approximately $37.42 million.

Because 13F filings are backward-looking documents, they show an investor's portfolio as of the end of the reporting period—in this case, May 15, 2026—and may not reflect current holdings or real-time market strategies.

Design Therapeutics Stock Action

On Sunday, shares of Design Therapeutics were priced at $14.47. The stock has experienced notable movement over the past year, trading between a 52-week low of $5.28 and a 52-week high of $17.25. Investors tracking the company's momentum will note that the stock is currently trading above both its 50-day moving average of $13.82 and its 200-day moving average of $11.89. The company has a total market capitalization of approximately $785.4 million.

Recent Earnings and Financial Health

Design Therapeutics is still in its clinical stage and does not yet generate a profit. The company reported an earnings per share (EPS) of -$1.18, and it has no meaningful price-to-earnings (P/E) ratio because of these net losses. Its return on equity stands at -34.1%. However, the biotech firm maintains a highly liquid balance sheet to fund its ongoing research, boasting a quick ratio of 18.61 and a current ratio of 18.86. The company is scheduled to report its next round of quarterly financial results on November 5, 2026.

Analysts Set New Price Targets

Wall Street analysts have expressed strong confidence in the biotechnology company. On October 2, 2026, Wells Fargo initiated coverage on Design Therapeutics with an Overweight rating and set a price target of $26.00 per share. Across the wider financial community, the stock currently commands a consensus "strong buy" recommendation based on six analyst opinions. The average price target among these analysts is $21.00, with individual targets ranging from a low of $20.00 to a high of $22.00.

Targeting Genetic Diseases

Based in Carlsbad, California, Design Therapeutics focuses on developing small molecule therapeutic drugs to treat serious genetic disorders. The company uses its proprietary GeneTAC platform to design therapies targeting inherited diseases caused by nucleotide repeat expansion. Its current pipeline includes candidate treatments for progressive and degenerative conditions such as Friedreich Ataxia, Myotonic Dystrophy Type-1, Fuchs Endothelial Corneal Dystrophy, and Huntington's disease.

What's Ahead for Design Therapeutics, Inc.

Market observers will likely watch Design Therapeutics' upcoming clinical trial data and pipeline updates alongside its November 5, 2026 earnings report to see if the company's scientific progress justifies the optimism of major institutional backers like Baker Bros. Advisors. While institutional accumulation often suggests confidence in a company's pipeline, individual investors should remember that quarterly filings represent a historical snapshot rather than a current guarantee of ownership.